HR-Positive and Triple-Negative Metastatic Breast Cancer — An Interview with Dr Laura Huppert on Optimal Integration of ADCs into Treatment

Featuring an interview with Dr Laura Huppert, including the following topics:

• General overview of antibody-drug conjugate (ADC) structure and function; mechanisms of resistance to ADCs (0:00)
• Preventing and managing toxicities associated with trastuzumab deruxtecan (5:44)
• Selecting between sacituzumab govitecan and datopotamab deruxtecan for patients with metastatic breast cancer; common toxicities associated with these 2 agents (9:30)
• Potential use of ADCs in the first line for metastatic triple-negative breast cancer (mTNBC) (16:13)
• Case: A woman in her mid 40s with mTNBC receives sacituzumab govitecan and pembrolizumab in the first-line setting (18:25)
• CNS penetration and activity of ADCs in the treatment of breast cancer (22:27)
• Use of trastuzumab deruxtecan for HER2-ultralow mTNBC; promising trials of ADCs and other therapies for mTNBC (24:24)
• Treatment options in the second line and beyond for patients with HR-positive mBC that is HER2-negative, HER2 low or HER2 ultralow (27:05)
• Case: A woman in her late 50s with HR-positive, HER2-low mBC experiences disease progression on multiple lines of therapy (30:51)
• Ongoing evaluation of ADCs in the localized disease setting (35:42)
• Novel therapeutic approaches for leptomeningeal disease in patients with breast cancer (38:38)

CME information and select publications